X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Zinforo (ceftaroline fosamil) for the Treatment of Complicated Skin and Soft Tissue Infections

Yuvraj_pawp by Yuvraj_pawp
8th August 2014
in Europe, Projects

Zinforo (ceftaroline fosamil) is a new intravenous cephalosporin antibiotic indicated for the treatment of serious skin infections or community-acquired pneumonia. It was developed by AstraZeneca in collaboration with Forest Laboratories.
In August 2012, AstraZeneca received marketing authorisation for Zinforo from the European Commission, for the treatment of adult patients with complicated skin and soft tissue infections (cSSTI) or community-acquired pneumonia (CAP).

Complicated skin and soft tissue infection (cSSTI)

 

cSSTIs are infections of the skin and underlying soft tissues, such as fascia and muscle layers, which are difficult to treat. cSSTIs represent about 12% of all antibiotic-treated hospital patients in Europe.

Community-acquired pneumonia (CAP)

 

“Zinforo (ceftaroline fosamil) is a new intravenous cephalosporin antibiotic indicated for the treatment of serious skin infections or community-acquired pneumonia.”

Community-acquired pneumonia (CAP) is an infection of the lungs. The annual incidence of the disease is estimated to be between two and 12 cases per 1,000 inhabitants in Europe. The incidence of CAP is also found to be four-times higher in the elderly population than in younger populations. About 30% of the population in Europe is expected to reach elderly status by 2060, and the burden of CAP is expected to be more significant in future.

The treatment for both cSSTI and CAP diseases is associated with considerable morbidity, mortality, resource-use and healthcare costs, despite the availability of numerous antibiotics.

Zinforo’s mechanism of action

 

Zinforo contains a form of cephalosporin antibiotic that works by inhibiting and binding-to penicillin-binding proteins (PBPs), which play an important role in bacterial cell wall synthesis and repair. The drug helps reduce bacterial cell replication or cell death. It also contributes to the bactericidal activity against the common causative pathogens of cSSTI and CAP.

Ceftaroline fosamil clinical trials

 

AstraZeneca and Forest Laboratories conducted numerous clinical trials on Zinforo to establish the efficacy and safety of the drug. The European Commission’s approval of Zinforo was based on data from four phase III clinical trials, which included two trials (CANVAS 1 and 2) on cSSTI, and two trials (FOCUS 1 and 2) on CAP.

“Zinforo contains a form of cephalosporin antibiotic that works by inhibiting and binding-to penicillin-binding proteins (PBPs), which play an important role in bacterial cell wall synthesis and repair.”

The first CANVAS study was a randomised and double-blind clinical study. It enrolled 702 patients with cSSTI. About 353 patients were administered with Zinforo, and 349 received vancomycin plus aztreonam.

The study’s results showed that Zinforo achieved high clinical cure and microbiological success rates, and was efficacious for cSSTIs caused by MRSA and other common cSSTI pathogens. It was well-tolerated and proved to be a potential monotherapy alternative for the treatment of cSSTI.

The second CANVAS study was also a randomised and double-blind clinical study. It enrolled 694 patients with cSSTI. About 348 patients were administered with Zinforo and 346 were given vancomycin plus aztreonam.

The results demonstrated that Zinforo showed high clinical cure and microbiological success rates in treating cSSTIs caused by MRSA. It was also found to be effective against other common cSSTI pathogens.

The first FOCUS study was a multicentre, randomised, double-blind clinical study. It enrolled 613 patients, to establish the efficacy and safety of Zinforo, versus ceftriaxone, in treating CAP. In the study, about 298 patients were administered with Zinforo, and 308 were administered with ceftriaxone.

The study’s results established that Zinforo showed high clinical cure and microbiological response rates in hospitalised patients with CAP. It proved to be an effective and well-tolerated treatment option.

The second FOCUS study was a randomised, double-blinded, and multicentre study. It enrolled 627 patients with CAP of PORT risk class III or IV. About 315 patients were administered with Zinforo and 307 received ceftriaxone.

The results of the study revealed that Zinforo achieved high clinical cure and microbiological response rates in CAP patients. Zinforo was well-tolerated, with a safety profile that is similar to that of ceftriaxone and other cephalosporins.
The results of the studies demonstrated the clinical efficacy of Zinforo in treating cSSTI and CAP with the recognised tolerability profile of the cephalosporin class.

 

International commerical rights to Zinforo

In 2009, Forest Laboratories out-licensed AstraZeneca the exclusive worldwide commercial rights, as well as co-exclusive development rights, for Zinforo, excluding US, Canada and Japan. In March 2011, Forest launched ceftaroline fosamil in the US under the trade name Teflaro for the same indication.

Zinforo is the only approved cephalosporin monotherapy in Europe. It is approved in all 27 European Union member states and Iceland, Liechtenstein and Norway.

Tags: Europe
Previous Post

Uceris (Budesonide) for Treating Ulcerative Colitis

Next Post

Wilate, von Willebrand Factor/Coagulation Factor Concentrate

Related Posts

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials
Europe

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

26th April 2021
Sputnik V: World's First COVID-19 Vaccine Now Available to Public in Russia
Europe

Sputnik V: World’s First COVID-19 Vaccine Now Available to Public in Russia

26th September 2020
AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine
Europe

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

21st September 2020
Gilead's drug remdesivir gets US FDA's emergency use authorisation for COVID-19
Europe

Gilead’s drug remdesivir gets US FDA’s emergency use authorisation for COVID-19

4th May 2020
Europe

Pharmintech 2019: Big increase in International Participation Expected

18th November 2018
Europe

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

17th August 2018
Next Post

Wilate, von Willebrand Factor/Coagulation Factor Concentrate

Latest News

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In